We are Sorry, This Page doesn't Exist
There’s new evidence that the dominant approach to Alzheimer’s may be completely wrong
Experts are questioning a major scientific theory of the disease, which could mean two Biogen drugs won’t be successful......»»
Cambridge"s Akcea rebounds with FDA approval of first drug
After having one of its drugs rejected by the FDA in August, Cambridge biotech Akcea Therapeutics Inc. turned the tide on Friday, receiving approval for another treatment for a rare genetic disease. The FDA approved Tegsedi, known generically as ino.....»»
Top Analyst Upgrades and Downgrades: Apple, Applied Materials, Biogen, CyberArk, Electronic Arts, Marathon, Nike, NXP Semiconductors and More
The top analyst upgrades, downgrades and other research calls from Friday included Apple, Applied Materials, Biogen, CyberArk, Electronic Arts, Marathon, Nike and NXP Semiconductors......»»
Biogen doubles down on Alzheimer"s with new collaboration deal
On the eve of biotech's biggest conference, Biogen has announced two drug development deals — worth up to almost $500 million combined — targeting Alzheimer's disease and other neurological disorders. Biogen (Nasdaq: BIIB) said Friday that i.....»»
Biogen Inks Two Deals to Make Drugs for Neurological Diseases
Biogen (BIIB) signs deals with C4 Therapeutics and Skyhawk Therapeutics to develop potential therapies for Alzheimer's disease (AD), Parki.....»»
The Analyst Landscape: 27 Takes On Biogen
Latest Ra.....»»
Kroger analyst: Shareholders could benefit if Albertsons deal is canceled
Kroger Co. shareholders could win out if the company fails in its bid to acquire Albertsons Cos. Inc., an analyst said......»»
4 Reasons Why This Zscaler Analyst Is Turning Bullish: "Q1 Feedback Is Positive"
Zscaler, considered a "Top Pick on the Zacks Analyst Blog," is a leader in the SASE (Secure Access Service Edge) market. L.....»»
Rare Disease-Focused-Ultragenyx Pharmaceutical Stock Falls On Serious Adverse Events In Eaarly Genetic Disorder Study
New data from Phase 1/2 study of GTX-102 for Angelman syndrome shows rapid and sustained improvement in patients, exceeding natural history data. read more.....»»
Marvell Tech Set for Major Growth with AI Accelerators for Amazon, Google, and Potential Microsoft Deal: Analysts
Analyst reiterates Buy rating on Marvell with $95 PT. Marvell's AI event unveils growth opportunities and new customers. Stock gained 80% in 1 yr. Latest Ratings .....»»
Cartesian Therapeutics" Rare Disease Candidate Shows Long Lasting Benefit Over Argenx"s Vyvgart, Analyst Initiates With Buy
Cartesian Therapeutics' autoimmu.....»»
Amazon Analyst Reacts To MGM Studios Buyout Reports
Amazon.com, Inc. (NASDAQ: AMZN) shares traded slightly higher on Tuesday morning after sources reported on Monday the tech giant is nearing a deal to acquire MGM St.....»»
Applied Genetic CFO Bill Sullivan to leave, Jerry Reynolds appointed to CAO
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Applied Genetic reports Q1 EPS (41c), consensus (40c)
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Biogen"s Retinal Disease Gene Therapy Flunks Mid-Stage Study
Biogen Inc (NASDAQ: BIIB) has announced topline results from the Phase 2/3 XIRIUS study evaluating cotoretigene toliparvovec (BIIB112), a gene therapy being investigated as a one-time therapy for patients w.....»»
Biogen"s Retinal Disease Gene Therapy Flunks Mid-Stage Study
read more.....»»
Eli Lilly CEO David Ricks On Alzheimer’s Disease Drugs
CNBC transcript: Eli Lilly And Co (NYSE:LLY) Chairman & CEO David Ric.....»»